PD1A Stock Chart & Stats
€19.40
-€0.20(-1.02%)
At close: 4:00 PM EDT
€19.40
-€0.20(-1.02%)
Day’s Range― - ―
52-Week Range€15.20 - €21.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€2.77B
Enterprise Value€6.00K
Total Cash (Recent Filing)€254.17M
Total Debt (Recent Filing)€912.82M
Price to Earnings (P/E)24.0
Beta0.60
Next Earnings
Aug 24, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding140,313,830
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)1.47
Price to Sales (P/S)1.45
P/FCF Ratio17.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.86Price Target Upside7.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.93
Revenue Forecast (FY)€1.32B
Bulls Say, Bears Say
Bulls Say
Margin ExpansionMaterial margin expansion reflects stronger pricing, procurement savings and operational leverage. Sustained higher EBIT/GPADE margins enhance cash flow generation capacity and provide structural buffer versus commodity price swings, aiding long-term profitability and reinvestment.
Cash Conversion & LeverageHigh cash conversion with modest net leverage signals durable free-cash-generation capacity and financial flexibility. This supports capex for growth (e.g., new lines), share buybacks and downside protection during volume cycles without materially weakening the balance sheet.
Product & Integration StrengthSuccessful KBU integration driving cost synergies plus active new-product launches and added manufacturing capacity in India strengthen competitive position. These structural moves expand higher-margin portfolio and reduce supply risk, supporting sustainable revenue mix improvement.
Bears Say
Free Cash Flow DeclineA material drop in free cash flow growth weakens internal funding for capex, dividends and buybacks if persistent. Even with strong operating cash conversion, falling FCF growth suggests timing or working-capital pressures that can constrain capital allocation flexibility over coming quarters.
Volume Pressure In Commodity ProductsOngoing declines in commodity exam glove volumes reduce revenue visibility and compress overall margins if higher-value sales don't scale. Structural volume weakness in price-sensitive segments increases reliance on pricing and mix improvements to sustain revenue growth.
Tariff & FX HeadwindsAn $80M annualized tariff exposure and multi-million-dollar FX headwinds create recurring cost pressure and may dampen demand in export-dependent markets. These structural external costs force sustained pricing actions and margin mitigation that could limit volume recovery in some regions.
Ansell News
PD1A FAQ
What was Ansell’s price range in the past 12 months?
Ansell lowest stock price was €15.20 and its highest was €21.00 in the past 12 months.
What is Ansell’s market cap?
Ansell’s market cap is €2.77B.
When is Ansell’s upcoming earnings report date?
Ansell’s upcoming earnings report date is Aug 24, 2026 which is in 22 days.
How were Ansell’s earnings last quarter?
Ansell released its earnings results on Feb 15, 2026. The company reported €0.575 earnings per share for the quarter, beating the consensus estimate of €0.553 by €0.022.
Is Ansell overvalued?
According to Wall Street analysts Ansell’s price is currently Undervalued.
Does Ansell pay dividends?
Ansell does not currently pay dividends.
What is Ansell’s EPS estimate?
Ansell’s EPS estimate is 0.66.
How many shares outstanding does Ansell have?
Ansell has 140,313,830 shares outstanding.
What happened to Ansell’s price movement after its last earnings report?
Ansell reported an EPS of €0.575 in its last earnings report, beating expectations of €0.553. Following the earnings report the stock price went up 8.585%.
Which hedge fund is a major shareholder of Ansell?
Currently, no hedge funds are holding shares in DE:PD1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ansell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.86 (7.55% Upside)
€20.86 (7.55% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.18%
12-Months-Change
Fundamentals
Return on Equity
2.33%
Trailing 12-Months
Asset Growth
1.60%
Trailing 12-Months
Company Description
Ansell
Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The company's operations are divided into two principal divisions: Healthcare and Industrial. The Healthcare division focuses on crafting and distributing products such as surgical, single-use, and examination gloves, alongside specialized cleanroom and sterile gloves and apparel. These offerings cater to a diverse clientele including medical facilities, surgical clinics, dental offices, veterinary practices, emergency services, research laboratories, and pharmaceutical and life science firms. Conversely, the Industrial segment provides hand and chemical protective gear designed for a wide array of demanding applications, from the automotive, chemical, and metal fabrication sectors to machinery, food processing, construction, mining, oil and gas industries, and first responders. Established in 1893 and headquartered in Richmond, Australia, the company was initially known as Pacific Dunlop Limited before rebranding to Ansell Limited in 2002. P. D. Holdings Pty. Ltd. currently operates as a subsidiary of Ansell Limited.
PD1A Stock 12 Month Forecast
Average Price Target
€20.86
▲(7.55% Upside)
Technical Analysis
Nanosonics Limited
―
Medical Developments International Limited
―
Trajan Group Holdings Ltd
―
CleanSpace Holdings Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―







